Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, FY2023
1,017
Period ended Dec 31, 2023
Change on a year earlier
+2.9%
988 in FY2022
History
5 years
Since FY2019
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1,017 | +2.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 988 | +2.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 969 | +12.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 860 | +15.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 742 | – | Form 10-K (filed 2022-02-23) ↗ |
Breakdown
What makes up total hbv / hdv franchise (legacy sub-franchise breakout) ($m)
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)418 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)133 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)466 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%)2.0% · FY2022
- Viread (tenofovir disoproxil fumarate — legacy breakout) ($M)83 · FY2023
- Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) ($M)72 · FY2023
Cite this data
StockData. (2026). Gilead Sciences Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M), annual FY2019–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_hbv_hdv_total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.